MARKET

TRVN

TRVN

Trevena Inc
NASDAQ
3.450
-0.005
-0.14%
After Hours: 3.350 -0.1 -2.90% 18:26 12/01 EST
OPEN
3.440
PREV CLOSE
3.455
HIGH
3.500
LOW
3.385
VOLUME
17.24K
TURNOVER
0
52 WEEK HIGH
19.00
52 WEEK LOW
2.380
MARKET CAP
26.61M
P/E (TTM)
-0.3793
1D
5D
1M
3M
1Y
5Y
BRIEF-Trevena Regains Compliance With Nasdaq Listing Requirements
Reuters · 2d ago
Trevena Regains Listing Compliance with Nasdaq Stock Market
Trevena Regains Listing Compliance with Nasdaq Stock Market
MT Newswires · 2d ago
InMed, AirSculpt top healthcare gainers; BrainsWay, Brookdale among losers
Seekingalpha · 11/16 15:01
Trevena launches $8M securities offering
Seekingalpha · 11/16 13:09
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/16 13:08
Trevena, Inc. Announces $8M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Benzinga · 11/16 13:01
Trevena Launches $8 Million Registered Direct Stock Offering; Shares Fall
Trevena Launches $8 Million Registered Direct Stock Offering; Shares Fall
MT Newswires · 11/16 10:33
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
Benzinga · 11/10 18:05
More
About TRVN
Trevena Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. It is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. It is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. It is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine. The Company is focused on exploring other formulations, such as transmucosal or transdermal administration for breakthrough or chronic pain, respectively. The Company is in the Phase III clinical program for OLINVO with the enrollment of patients in the ATHENA study, a Phase III, open-label, multicenter study.

Webull offers kinds of Trevena Inc stock information, including NASDAQ:TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.